P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC: Topic: EGFR RES
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.11.1787
Abstract: Results: At the data cut-off (Aug 1, 2016), 33 patients were enrolled at five capmatinib BID/EGF816 QD mg dose levels (200/50 [n1⁄44]; 200/100 [n1⁄45]; 400/75 [n1⁄43]; 400/100 [n1⁄416]; 400/150 mg [n1⁄45]); 18/33 (55%) patients discontinued… read more here.
Keywords: 400 150; egfr; dose level; 400 100 ... See more keywords